Dr. Sudhir Paul is a founder and Chief Scientist at Covalent Bioscience, a company developing Catalytic Immunotherapy/Electrophilic Vaccine technologies. He discovered and invented the basic science concepts underlying these technologies as former Director and Professor at the Chemical Immunology Research Center, University of Texas Houston Medical School. He has authored about 200 original research articles, edited numerous books and conference proceedings on catalytic antibodies and electrophilic vaccines, and he is an influential opinion maker and reviewer in these fields in behalf of the NIH, other funding agency around the world, and scientific journals. Dr. Paul’s research was funded continuously by the NIH, non-profit foundations and for-profit companies since 1983. He now devotes himself full-time to translating the know-how into healthy aging and meeting other medical needs.